METHODS OF VACCINATION AND USE OF CD47 BLOCKADE

1 . A pharmaceutical composition comprising an isolated modified cell of leukemic origin comprising a downregulated CD47 pathway, and a pharmaceutically acceptable excipient.

2 . The pharmaceutical composition of claim 1 , wherein the downregulated CD47 pathway is a result of the depletion and/or inhibition of a member of the CD47 pathway, optionally wherein:

the member of the CD47 pathway is CD47;

the downregulated CD47 pathway is the result of the depletion and/or inhibition of CD47 and/or a member of the CD47 pathway; or

the downregulated CD47 pathway is mediated by an agent that depletes and/or inhibits CD47 and/or a member of the CD47 pathway.

3 - 5 . (canceled)

6 . The pharmaceutical composition of claim 2 , wherein the agent that depletes CD47 and/or a member of the CD47 pathway is selected from the group consisting of an antibody, a small molecule, a small RNA, or an engineered nuclease system, optionally wherein:

the antibody is an anti-CD47 antibody;

the small RNA is a small interfering RNA (siRNA) or a microRNA (miRNA); and/or

the engineered nuclease system is selected from the group consisting of a meganuclease system, a zinc finger nuclease (ZFN) system, a transcription activator-like effector nuclease (TALEN) system, and a CRISPR system, optionally wherein:

the engineered nuclease system mediates an insertion and/or deletion in a CD47 gene locus and/or the gene locus of a member of the CD47 pathway of the modified cell;

the engineered nuclease system mediates an insertion and/or deletion in a CD47 gene locus of the modified cell; and/or

the engineered nuclease system is a CRISPR system.

7 - 12 . (canceled)

13 . A pharmaceutical composition comprising:

a modified cell of leukemic origin comprising an insertion and/or deletion in a CD47 gene locus, wherein the insertion and/or deletion in the CD47 gene locus results in downregulated expression of CD47;

a modified cell of leukemic origin and an anti-CD47 antibody; or

a modified cell of leukemic origin comprising a downregulated CD47 pathway and an anti-CD47 antibody.

14 . The pharmaceutical composition of claim 13 , wherein the insertion and/or deletion in a CD47 gene locus is mediated by the repair of a double strand break in the CD47 gene locus, optionally wherein:

the insertion and/or deletion in the CD47 gene locus is mediated by an engineered nuclease system,

the engineered nuclease system is selected from the group consisting of a meganuclease system, a zinc finger nuclease (ZFN) system, a Transcription activator-like effector nuclease (TALEN) system, and a CRISPR system,

the engineered nuclease system is a CRISPR system; and/or

the repair is via non-homologous end joining (NHEJ) and homology directed repair (HDR).

15 - 18 . (canceled)

19 . The pharmaceutical composition of claim 13 , further comprising:

an agent that depletes and/or inhibits CD47 and/or a member of the CD47 pathway, optionally wherein the agent that depletes and/or inhibits CD47 and/or a member of the CD47 pathway is an anti-CD47 antibody; and/or

a pharmaceutically acceptable excipient, optionally wherein the pharmaceutical composition comprises a cryopreservation agent.

20 - 24 . (canceled)

25 . The pharmaceutical composition of claim 1 , wherein the modified cell comprises at least one tumor associated antigen or a nucleic acid encoding at least one tumor associated antigen, wherein the tumor associated antigen is selected from the group consisting of WT-1, MUC-1, RHAMM, PRAME, p53, and Survivin, optionally wherein the modified cell:

comprises WT-1, MUC-1, PRAME, and Survivin,

comprises an exogenous antigen, wherein the exogenous antigen is a tumor-associated antigen;

comprises a dendritic cell phenotype;

comprises a mature dendritic cell phenotype;

comprises a genetic aberration between chromosome 11p15.5 to 11p12, wherein the genetic aberration encompasses about 16 Mb of genomic regions;

is CD34-positive, CD1a-positive, and CD83-positive;

expresses a cell surface marker selected from the group consisting of DC-SIGN, Langerin, CD80, CD86, CD70, CD40, and any combination thereof;

is CD34-positive, CD la-positive, CD83-positive, CD80-positive, CD86-positive, and CD40-positive;

is CD14-negative;

is derived from the DCOne cell line;

is non-proliferating; or

has been irradiated.

26 - 39 . (canceled)

40 . A method of producing a modified cell of leukemic origin comprising a downregulated CD47 pathway, comprising:

incubating a precursor cell under conditions that allow for the differentiation of the precursor cell into an immature cell; and

incubating the immature cell in the presence of an agent that depletes and/or inhibits CD47 and/or a member of the CD47 pathway, and under conditions that allows for the maturation of the immature cell, thereby producing the modified cell comprising a downregulated CD47 pathway.

41 . The method of claim 40 , wherein the agent that depletes and/or inhibits CD47 and/or a member of the CD47 pathway is selected from the group consisting of an antibody, a small molecule, a small RNA, or an engineered nuclease system, optionally wherein:

the antibody is an anti-CD47 antibody;

the small RNA is a small interfering RNA (siRNA) or a microRNA (miRNA); or the engineered nuclease system mediates an insertion and/or deletion in a CD47 gene locus and/or the gene locus of a member of the CD47 pathway of the modified cell, optionally wherein the engineered nuclease system:

mediates an insertion and/or deletion in a CD47 gene locus of the modified cell;

is selected from the group consisting of a meganuclease system, a zinc finger nuclease (ZFN) system, a transcription activator-like effector nuclease (TALEN) system, and a CRISPR system; and/or

is a CRISPR system.

42 - 47 . (canceled)

48 . A pharmaceutical composition comprising the modified cell produced by the method of claim 40 , optionally further comprising a pharmaceutiaccly accptable excipient and/or a cryopreservation agent.

49 . (canceled)

50 . (canceled)

51 . A method of enhancing an immune response in a subject in need thereof or treating or preventing cancer in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 1 .

52 . (canceled)

53 . A method of enhancing an immune response in a subject in need thereof, comprising:

administering to the subject a first composition comprising a modified cell of leukemic origin comprising a downregulated CD47 pathway; or

administering to the subject a first composition comprising a modified cell of leukemic origin, and an agent that depletes and/or inhibits CD47 and/or a member of the CD47 pathway.

54 . The method of claim 53 , wherein the first composition further comprises an agent that depletes and/or inhibits CD47 and/or a member of the CD47 pathway, optionally wherein:

the method further comprises administering to the subject an effective amount of a second composition comprising an agent that depletes and/or inhibits CD47;

the first composition and the second composition are administered simultaneously;

the first composition is administered before the second composition; or

the first composition is administered after the second composition.

55 - 59 . (canceled)

60 . The method of claim 53 , wherein the modified cell comprises at least one tumor associated antigen or a nucleic acid encoding the tumor associated antigen, wherein the tumor associated antigen is associated with the tumor in the subject, optionally wherein the modified cell comprises at least one tumor associated antigen or a nucleic acid encoding the tumor associated antigen, wherein the tumor associated antigen is not associated with the tumor in the subject.

61 . (canceled)

62 . The method of claim 54 , wherein:

the first composition and/or the second composition is administered via a route selected from the group consisting of intramuscular, subcutaneous, intravenous, intraarterial, intraperitoneal, intrasternal, intradermal, transcutaneous, transdermal, delivery to the interstitial space of a tissue, and delivery to a non-tumor tissue;

the first composition and/or the second composition is administered intravenously;

the first composition and/or the second composition is administered intradermally, the first composition and/or the second composition is administered intramuscularly; or

the first composition and/or the second composition is administered intratumorally.

63 . (canceled)

64 . The method of claim 62 , wherein:

the first composition and/or the second composition is prepared for intravenous administration;

the first composition and/or the second composition comprises a diluent or solvent acceptable for intravenous administration;

the first composition and/or the second composition is prepared for intradermal administration, optionally wherein the first composition and/or the second composition comprises a diluent or solvent acceptable for intradermal administration;

the first composition and/or the second composition is prepared for intramuscular administration, optionally wherein the first composition and/or the second composition comprises a diluent or solvent acceptable for intramuscular administration; or

d) the first composition and/or the second composition is prepared for intratumoral administration, optionally wherein the first composition and/or the second composition comprises a diluent or solvent acceptable for intratumoral administration.

65 - 74 . (canceled)

75 . The method of claim 54 , wherein:

the agent that depletes and/or inhibits CD47 is selected from the group consisting of an antibody, a small molecule, a small RNA, or an engineered nuclease system,

the antibody is an anti-CD47 antibody,

the small RNA is a small interfering RNA (siRNA) or a microRNA (miRNA),

the engineered nuclease system mediates an insertion and/or deletion in a CD47 gene locus and/or the gene locus of a member of the CD47 pathway of the modified cell, optionally wherein the engineered nuclease system:

mediates an insertion and/or deletion in a CD47 gene locus of the modified cell,

is selected from the group consisting of a meganuclease system, a zinc finger nuclease (ZFN) system, a transcription activator-like effector nuclease (TALEN) system, and a CRISPR system; or

is a CRISPR system.

76 - 81 . (canceled)

82 . The method of claim 54 , wherein the agent that depletes and/or inhibits CD47 comprises a viral vector comprising a nucleic acid encoding an anti-CD47 antibody, a CD47-targeting small RNA, or a CD47-targeting engineered nuclease system, optionally wherein:

the viral vector is derived from a virus selected from the group consisting of a retrovirus, an adenovirus, an adeno-associated virus, and a herpes simplex virus;

the CD47-targeting small RNA is a small interfering RNA (siRNA) or a microRNA (miRNA); and/or

wherein the CD47-targeting engineered nuclease system mediates an insertion and/or deletion in a CD47 gene locus of the modified cell, optionally wherein the CD47-targeting engineered nuclease system is selected from the group consisting of a meganuclease system, a ZFN system, a TALEN system, and a CRISPR system, or is a CRISPR system.

83 - 87 . (canceled)

88 . The method of claim 53 , wherein the modified cell comprises at least one tumor associated antigen or a nucleic acid encoding at least one tumor associated antigen, wherein the tumor associated antigen is selected from the group consisting of WT-1, MUC-1, RHAMM, PRAME, p53, and Survivin, optionally wherein the modified cell:

comprises WT-1, MUC-1, PRAME, and Survivin;

comprises an exogenous antigen, wherein the exogenous antigen is a tumor-associated antigen;

comprises a dendritic cell phenotype;

comprises a mature dendritic cell phenotype;

comprises a genetic aberration between chromosome 11p15.5 to 11p12, wherein the genetic aberration encompasses about 16 Mb of genomic regions;

is CD34-positive, CD1a-positive, and CD83-positive;

expresses a cell surface marker selected from the group consisting of DC-SIGN, Langerin, CD80, CD86, CD70, CD40, and any combination thereof;

is CD34-positive, CD1a-positive, CD83-positive, CD80-positive, CD86-positive, and CD40-positive;

is CD14-negative;

is derived from the DCOne cell line;

is non-proliferating; or

has been irradiated.

89102 . (canceled)

103 . The method of claim 53 , wherein the subject has previously suffered from the cancer, the subject has previously received treatment for the cancer, or the subject is suffering from relapse of the cancer, optionaly wherein:

the cancer is a tumor or a solid tumor, optionally wherein the solid tumor is selected from the group consisting of a sarcoma, a carcinoma, and a lymphoma; and/or

the subject is a human, a domesticated animal, or an animal suitable for veterinary healthcare.

104 - 110 . (canceled)